CR20140298A - Nuevo uso terapéutico de antagonistas del receptor p75 - Google Patents

Nuevo uso terapéutico de antagonistas del receptor p75

Info

Publication number
CR20140298A
CR20140298A CR20140298A CR20140298A CR20140298A CR 20140298 A CR20140298 A CR 20140298A CR 20140298 A CR20140298 A CR 20140298A CR 20140298 A CR20140298 A CR 20140298A CR 20140298 A CR20140298 A CR 20140298A
Authority
CR
Costa Rica
Prior art keywords
therapeutic use
new therapeutic
receiver antagonists
antagonists
receiver
Prior art date
Application number
CR20140298A
Other languages
English (en)
Inventor
Roberta Avallone
Marco Baroni
Tiziano Croci
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47429839&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR20140298(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of CR20140298A publication Critical patent/CR20140298A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención se refiere al uso de un antagonista del receptor p75 o sus sales farmacéuticamente aceptables apra la preparación de un medicamento par auso en el tratamiento y/o prevención de vejiga sobreactiva.
CR20140298A 2011-12-20 2014-06-19 Nuevo uso terapéutico de antagonistas del receptor p75 CR20140298A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11306709.4A EP2606894A1 (en) 2011-12-20 2011-12-20 Novel therapeutic use of p75 receptor antagonists
PCT/EP2012/076494 WO2013092918A1 (en) 2011-12-20 2012-12-20 Novel therapeutic use of p75 receptor antagonists

Publications (1)

Publication Number Publication Date
CR20140298A true CR20140298A (es) 2014-10-29

Family

ID=47429839

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20140298A CR20140298A (es) 2011-12-20 2014-06-19 Nuevo uso terapéutico de antagonistas del receptor p75

Country Status (24)

Country Link
US (2) US20140296513A1 (es)
EP (2) EP2606894A1 (es)
JP (2) JP6275649B2 (es)
KR (1) KR20140103151A (es)
CN (1) CN104144688B (es)
AR (1) AR089344A1 (es)
AU (2) AU2012356922B2 (es)
BR (1) BR112014014933A2 (es)
CA (1) CA2859582A1 (es)
CL (1) CL2014001619A1 (es)
CO (1) CO6990740A2 (es)
CR (1) CR20140298A (es)
DO (1) DOP2014000137A (es)
EA (1) EA028616B1 (es)
HK (1) HK1198580A1 (es)
IL (1) IL233189A0 (es)
MA (1) MA35850B1 (es)
MX (1) MX2014007673A (es)
PE (1) PE20141854A1 (es)
PH (1) PH12014501390A1 (es)
SG (1) SG11201403390QA (es)
TN (1) TN2014000269A1 (es)
UY (1) UY34535A (es)
WO (1) WO2013092918A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2606894A1 (en) * 2011-12-20 2013-06-26 Sanofi Novel therapeutic use of p75 receptor antagonists
EP3634420A1 (en) 2017-06-06 2020-04-15 Urovant Sciences GmbH Use of vibegron to treat overactive bladder
JP7530182B2 (ja) * 2020-02-06 2024-08-07 株式会社東芝 生体適合部材

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3236243A1 (de) 1982-09-30 1984-04-05 Merck Patent Gmbh, 6100 Darmstadt Schwefelhaltige indolderivate
FR2744448B1 (fr) 1996-02-02 1998-04-24 Pf Medicament Nouvelles piperidines derivees d'aryl piperazine, ainsi que leur procede de preparation, les compositions pharmaceutiques et leur utilisation comme medicaments
AU728523C (en) 1996-10-21 2001-08-09 Nps Pharmaceuticals, Inc. Neurotrophin antagonist compositions
US6613942B1 (en) 1997-07-01 2003-09-02 Novo Nordisk A/S Glucagon antagonists/inverse agonists
BR9810378A (pt) 1997-07-01 2000-08-29 Novo Nordisk As Composto,uso do mesmo, composição farmacêutica, e, processos de tratar a diabete do tipo i ou do tipo ii, de tratar a hiperglicemia, e de diminuir a glicose do sangue em um mamìfero
DE19826841A1 (de) 1998-06-16 1999-12-23 Merck Patent Gmbh Arylalkanoylpyridazine
GB9905010D0 (en) 1999-03-04 1999-04-28 Merck Sharp & Dohme Therapeutic agents
AU4198400A (en) 1999-04-06 2000-10-23 Krenitsky Pharmaceuticals Inc. Neurotrophic thio substituted pyrimidines
US6468990B1 (en) 1999-05-17 2002-10-22 Queen's University At Kingston Method of inhibiting binding of nerve growth factor to p75 NTR receptor
FR2803593B1 (fr) 2000-01-06 2002-02-15 Sanofi Synthelabo Nouvelles tetrahydropyridines, procede pour leur preparation et compositions pharmaceutiques les contenant
UA77526C2 (en) 2002-06-07 2006-12-15 Sanofi Aventis Substituted derivatives of 1-piperazineacylpiperidine, a method for the preparation thereof and their use in therapy
FR2862967B1 (fr) 2003-12-01 2006-08-04 Sanofi Synthelabo Derives de (4-phenylpiperazin-1-yl)acylpiperidine, leur preparation et leur application en therapeutique
FR2862968B1 (fr) 2003-12-01 2006-08-04 Sanofi Synthelabo Derives de 4-[(arylmethyl)aminomethyl]piperidine, leur preparation et leur application en therapeutique
JP2008508358A (ja) 2004-08-02 2008-03-21 オーエスアイ・ファーマスーティカルズ・インコーポレーテッド アリール−アミノ置換ピロロピリミジンマルチキナーゼ阻害化合物
WO2007030939A2 (en) * 2005-09-15 2007-03-22 Painceptor Pharma Corporation Methods of modulating neurotrophin-mediated activity
JP2011513421A (ja) 2008-03-05 2011-04-28 ターガセプト，インコーポレイテッド サブタイプ選択的なジアザビシクロアルカンのアミド
WO2009120717A2 (en) 2008-03-24 2009-10-01 Medivation Technologies, Inc. Pyrido [3, 4-b] indoles and methods of use
CN101284838B (zh) 2008-06-06 2011-05-04 天津药物研究院 含噻吩并吡啶的哌嗪类衍生物、其制备方法和用途
FR2932482B1 (fr) * 2008-06-13 2010-10-08 Sanofi Aventis Nouveaux derives de (phenyl-3,6-dihydro-2h-pyridinyl)- (piperazinyl ponte)-1-alcanone et leur utilisation comme inhibiteurs de p75
FR2932481B1 (fr) 2008-06-13 2010-10-08 Sanofi Aventis Derives de 4-{2-°4-phenyl-3,6-dihydro-2h-pyridin-1-yl!-2- oxo-alkyl}-1-piperazin-2-one, leur preparation et leur application en therapeutique.
JP2010254641A (ja) * 2009-04-28 2010-11-11 Astellas Pharma Inc アゾールカルボキサミド化合物又はその塩
FR2953839A1 (fr) 2009-12-14 2011-06-17 Sanofi Aventis Nouveaux derives d'(heterocycle-piperidine condensee)-(piperazinyl)-1alcanone ou d'(heterocycle-pyrrolidine condensee)-(piperazinyl)-1alcanone et leur utilisation comme inhibiteurs de p75
FR2953836B1 (fr) 2009-12-14 2012-03-16 Sanofi Aventis Nouveaux derives (heterocycle-tetrahydro-pyridine)-(piperazinyl)-1-alcanone et (heterocycle-dihydro-pyrrolidine)-(piperazinyl)-1-alcanone et leur utilisation comme inhibiteurs de p75
EP2606894A1 (en) * 2011-12-20 2013-06-26 Sanofi Novel therapeutic use of p75 receptor antagonists

Also Published As

Publication number Publication date
US20140296513A1 (en) 2014-10-02
EP2793889A1 (en) 2014-10-29
JP6275649B2 (ja) 2018-02-07
UY34535A (es) 2013-07-31
IL233189A0 (en) 2014-07-31
AR089344A1 (es) 2014-08-13
CN104144688A (zh) 2014-11-12
US9763940B2 (en) 2017-09-19
KR20140103151A (ko) 2014-08-25
EP2606894A1 (en) 2013-06-26
MA35850B1 (fr) 2014-12-01
SG11201403390QA (en) 2014-07-30
PH12014501390A1 (en) 2014-09-22
AU2017248550A1 (en) 2017-11-09
NZ626485A (en) 2016-11-25
CO6990740A2 (es) 2014-07-10
HK1198580A1 (en) 2015-04-30
EA028616B1 (ru) 2017-12-29
CA2859582A1 (en) 2013-06-27
EA201491226A1 (ru) 2014-10-30
US20170056400A1 (en) 2017-03-02
CL2014001619A1 (es) 2014-10-17
JP2015500863A (ja) 2015-01-08
WO2013092918A1 (en) 2013-06-27
AU2012356922B2 (en) 2017-11-09
CN104144688B (zh) 2017-03-22
BR112014014933A2 (pt) 2017-06-13
DOP2014000137A (es) 2014-07-31
JP2018030865A (ja) 2018-03-01
MX2014007673A (es) 2014-11-14
AU2012356922A1 (en) 2014-07-17
TN2014000269A1 (en) 2015-09-30
PE20141854A1 (es) 2014-12-11

Similar Documents

Publication Publication Date Title
MX377410B (es) Antagonistas de receptores de integrina y sus metodos de uso.
NI201400108A (es) Compuestos de heterociclilo
BR112012032282A2 (pt) administração transdérmica de memantina
MD4539B1 (ro) 4-Fenilpiridine substituite pentru tratamentul bolilor asociate cu receptorul NK-1
AR092177A1 (es) Metodos para tratar o prevenir asma administrando un antagonista de il-4r
ECSP15008695A (es) Combinaciones farmacéuticas que comprenden un inhibidor de b-raf, un inhibidor de egfr y opcionalmente un inhibidor de pi3k-alfa
MX336497B (es) Compuestos de tetrahidro-pirido-piridina y tetrahidro-pirido-pirim idina y su uso como moduladores de los receptores de c5a.
SV2015005115A (es) Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades
EP2670458A4 (en) APPARATUS FOR MEDICAMENT ADMINISTRATION
MX354125B (es) Combinacion de un agonista opioide y un antagonista opioide en el tratamiento de la enfermedad de parkinson.
CL2015002733A1 (es) Composición farmacéutica de clorhidrato de s-cetamina.
BR112012028136A2 (pt) terapia de combinaçao
CO7131375A2 (es) Uracilos sustituidos bicíclicamente y uso de los mismos
CO6852025A2 (es) El anticuerpo neutralizador del receptor de prolactina mat3 y su uso terapéutico
PH12016502353A1 (en) Pharmaceutical composition
UY35211A (es) Compuestos tricíclicos
TW201613577A (en) Pharmaceutical combinations
UY35209A (es) Compuestos tricíclicos
UY33529A (es) Composiciones farmacéuticas para el tratamiento de enfermedades respiratorias e inflamatorias?
CR20140298A (es) Nuevo uso terapéutico de antagonistas del receptor p75
MY172809A (en) Spirothienopyran-piperidine derivatives as orl-1 receptor antagonists for their use in the treatment of alcohol dependence and abuse
AR090605A1 (es) Un antagonista del receptor h3 para uso en el tratamiento de la enfermedad de alzheimer
MX370451B (es) Cloruro de dietil-[6-(4-hidroxicarbamoil-fenil-carbamoiloxi metil)-naftalen-2-il-metil]-amonio para su uso en el tratamiento de distrofia muscular.
UY35196A (es) Nuevo uso de aclidinio
GT201500001A (es) Composiciones líquidas orales pediátricas que contienen nepadutant